{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatitis+A+vaccine",
    "query": {
      "intervention": "Hepatitis A vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 136,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatitis+A+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T21:02:32.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00000943",
      "title": "A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tetanus Toxoid Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A Vaccine (Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIV-1 Immunogen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": null,
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • New York, New York",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000943"
    },
    {
      "nct_id": "NCT01978093",
      "title": "Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neisseria Meningitidis",
        "Haemophilus Influenzae Type b"
      ],
      "interventions": [
        {
          "name": "Hib-MenCY-TT (MenHibrix®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PedvaxHIB®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 600,
      "start_date": "2014-02-01",
      "completion_date": "2016-03-18",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01978093"
    },
    {
      "nct_id": "NCT05095844",
      "title": "National Vaccine Adverse Event Reporting Survey and Etiology",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Vaccine Adverse Reaction",
        "Vaccine Reaction",
        "Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use",
        "Corona Virus Infection",
        "Blood Clot",
        "Thrombocytopenia",
        "Neuritis",
        "Vasculitis",
        "Influenza",
        "Guillain-Barré",
        "GWAS",
        "Genetic Sequencing"
      ],
      "interventions": [
        {
          "name": "vaccinated",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neuroganics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "5 Years to 99 Years"
      },
      "enrollment_count": 100000,
      "start_date": "2022-03-15",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 1,
      "location_summary": "Northglenn, Colorado",
      "locations": [
        {
          "city": "Northglenn",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095844"
    },
    {
      "nct_id": "NCT04843852",
      "title": "TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B",
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-10-16",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843852"
    },
    {
      "nct_id": "NCT06038617",
      "title": "Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fever After Vaccination",
        "Fever",
        "Seizures Fever"
      ],
      "interventions": [
        {
          "name": "mRNA COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Routine Childhood Vaccinations",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "4 Years",
        "sex": "ALL",
        "summary": "6 Months to 4 Years"
      },
      "enrollment_count": 347,
      "start_date": "2023-10-30",
      "completion_date": "2025-07-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06038617"
    },
    {
      "nct_id": "NCT01341275",
      "title": "Adolescents' Response to Hepatitis B Vaccine Booster Dose",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "hepatitis B vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "16 Years to 19 Years"
      },
      "enrollment_count": 400,
      "start_date": "2010-04",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2011-04-25",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01341275"
    },
    {
      "nct_id": "NCT03893448",
      "title": "Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections",
        "Pneumococcal Vaccines"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentacel™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RECOMBIVAX HB™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAQTA™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR II™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VARIVAX™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIBERIX™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "90 Days",
        "sex": "ALL",
        "summary": "42 Days to 90 Days"
      },
      "enrollment_count": 1720,
      "start_date": "2019-06-19",
      "completion_date": "2021-05-24",
      "has_results": true,
      "last_update_posted_date": "2023-07-28",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Opp",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893448"
    },
    {
      "nct_id": "NCT01627340",
      "title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Engerix™-B vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 667,
      "start_date": "2012-07-24",
      "completion_date": "2013-12-18",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 10,
      "location_summary": "Huntsville, Alabama • Stockbridge, Georgia • Boise, Idaho + 7 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Mishawaka",
          "state": "Indiana"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627340"
    },
    {
      "nct_id": "NCT00449124",
      "title": "TG4040 in Patients With Chronic HCV",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TG4040",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2019-01-23",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Cincinnati, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00449124"
    },
    {
      "nct_id": "NCT03393754",
      "title": "Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B Vaccines"
      ],
      "interventions": [
        {
          "name": "Hepatitis B Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VBI Vaccines Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1607,
      "start_date": "2017-12-13",
      "completion_date": "2019-04-08",
      "has_results": true,
      "last_update_posted_date": "2020-07-17",
      "last_synced_at": "2026-09-29T21:02:32.734Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Anaheim, California • DeLand, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03393754"
    }
  ]
}